Enlivex Therapeutics Ltd. (ENLV)
Automate Your Wheel Strategy on ENLV
With Tiblio's Option Bot, you can configure your own wheel strategy including ENLV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENLV
- Rev/Share 0.0
- Book/Share 1.0774
- PB 0.8539
- Debt/Equity 0.0226
- CurrentRatio 6.8421
- ROIC -0.663
- MktCap 21941908.0
- FreeCF/Share -0.6003
- PFCF -1.6693
- PE -1.3416
- Debt/Assets 0.0193
- DivYield 0
- ROE -0.5688
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally TMJ causes pain and stiffness in the jaw, making it difficult to chew TMJ osteoarthritis currently has no long-term effective treatments Ness-Ziona, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the temporomandibular joint …
Read More
About Enlivex Therapeutics Ltd. (ENLV)
- IPO Date 2014-07-31
- Website https://www.enlivex.com
- Industry Biotechnology
- CEO Dr. Oren Hershkovitz Ph.D.
- Employees 71